comparemela.com

Latest Breaking News On - Scott kollins - Page 2 : comparemela.com

Akili, Inc (NASDAQ:AKLI) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen and welcome to the Akili Interactive Labs Third Quarter 2023 Earnings Call.

New yorkUnited statesVikram purohitSantosh shanbhagMatt franklinCharles rhyeeScott kollinsDevices agencyCommunications for akiliAkili incAmerican academy of childMorgan stanleyJapan pharmaceuticalsCall transcript novemberAkili interactive labs third quarterCaty reid

Employees with ADHD Aren t Reaching Their Full Potential at Work, Akili Study Finds -October 12, 2023 at 08:02 am EDT

Respondents struggle with routine tasks, career setbacks, and limited treatment options; meanwhile, managers feel unprepared to provide support .

United statesScott kollinsOs appPublic health emergencyAkili incWakefield researchDrug administrationAkili managersAkili employeeBetter workplaceBusiness wireChief medical officerGoogle playAkili employee surveyAkili managers surveyEnforcement policy

Henderson woman with ADHD credits game app for helping her focus

Henderson woman with ADHD credits game app for helping her focus
lasvegassun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lasvegassun.com Daily Mail and Mail on Sunday newspapers.

Ann childressBarbara wagnerScott kollinsWagner facebookBehavioral medicine

Digital therapeutics companies like Akili are shifting gears

As the digital therapeutics industry deals with a lack of reimbursement pathways, companies like Akili Interactive are taking alternate approaches to growth.

Megan coderScott kollinsRick andersonJeanne shaheenDigital therapeutics allianceCenters for medicareExchange commission filingMedicaid servicesDrug administrationPear therapeuticMichael paceCapital hillDigital therapeutics actDigital therapeuticsAkili interactiveDrug administration cleared

SteadyMD, AmerisourceBergen partner for pharmacy telehealth and more digital health briefs

Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.

Scott kollinsChan chiuJenni zilkaBoehringer ingelheimAb health venturesClick therapeuticsClinical assessment interviewNegative symptoms

vimarsana © 2020. All Rights Reserved.